EUVIMEDEUVIMED entdecken
Crossref

Treatment of K562 Cells with ABL Kinase Inhibitors Reveals Differential Metabolic Profiles

Pranay Renukuntla iD, Sai Charitha Mullaguri, Divya Presingu, Rama Krishna Kancha, Jagadeshwar Reddy Thota iD

Drug Research · 01.03.2026 · 76 (02/03) · 99-101

DOI: 10.1055/a-2769-1965 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Research, erschienen am 01.03.2026. Verfasst von Pranay Renukuntla und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Analytical and Structural Chemistry, CSIR - Indian Institute of Chemical Technology, 500007, Hyderabad, India. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Proto-Oncogene Proteins c-abl, Metabolome. Die Arbeit nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

ABL kinase inhibitors have transformed the clinical management of chronic myelogenous leukemia; yet, the metabolic consequences of their use remain largely unexplored. In the current study, using K562 cell lines, the metabolic impact of five ABL kinase inhibitors, such as imatinib, dasatinib, nilotinib, ponatinib, and axitinib, was studied. Comparative metabolic profiling revealed both common and inhibitor-specific metabolic alterations. Pathway enrichment analysis identified significant downregulation in starch and sucrose metabolism, nucleotide sugar metabolism and sphingolipid metabolism. These results offered insights to guide the development of treatment strategies for overcoming the drug resistance in chronic myelogenous leukemia as well as managing the associated toxicities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Kinase InhibitorsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveProto-Oncogene Proteins c-ablMetabolomeAntineoplastic AgentsHumansK562 CellsPyrimidinesDrug Resistance, Neoplasm

Substanzen

Protein Kinase InhibitorsProto-Oncogene Proteins c-ablAntineoplastic AgentsPyrimidines

Autor:innen und Institutionen

  • Department of Analytical and Structural Chemistry, CSIR - Indian Institute of Chemical Technology, 500007, Hyderabad, India.
  • Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, 201002, Uttar Pradesh, India.
  • Molecular Medicine and Therapeutics Laboratory, CPMB, Osmania University, 500007, Hyderabad, India.

ORCID-Profile: Pranay Renukuntla, Jagadeshwar Reddy Thota

Zitieren

APA

Renukuntla, P., Mullaguri, S. C., Presingu, D., Kancha, R. K., & Thota, J. R. (2026). Treatment of K562 Cells with ABL Kinase Inhibitors Reveals Differential Metabolic Profiles. Drug Research, 76(02/03), 99-101. https://doi.org/10.1055/a-2769-1965

Vancouver

Renukuntla P, Mullaguri SC, Presingu D, Kancha RK, Thota JR. Treatment of K562 Cells with ABL Kinase Inhibitors Reveals Differential Metabolic Profiles. Drug Research. 2026;76(02/03):99-101. doi:10.1055/a-2769-1965

BibTeX
@article{Renukuntla2026,
  author = {Renukuntla, Pranay and Mullaguri, Sai Charitha and Presingu, Divya and Kancha, Rama Krishna and Thota, Jagadeshwar Reddy},
  title = {Treatment of K562 Cells with ABL Kinase Inhibitors Reveals Differential Metabolic Profiles},
  journal = {Drug Research},
  year = {2026},
  volume = {76},
  number = {02/03},
  pages = {99--101},
  doi = {10.1055/a-2769-1965}
}
Kostenlos starten →